According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

The takeover battle between Novo Nordisk and Pfizer to land weight-loss drug maker Metsera is a sign of "an accelerating M&A ...

Merck announced that sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago. The pharma giant also narrowed its full-year profit outlook ...

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

Dow Jones Top Company Headlines at 9 PM ET: Amazon Shares Surge on 13% Revenue Jump, Strong Cloud Sales | Apple ... The e-commerce giant said Amazon Web Services is growing at its fastest rate since ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...

Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.